ContributorsPublishersAdvertisers

Efficacy Sustained at 2 Years With Nivolumab Plus Chemo in Gastric/GEJ Cancer

targetedonc.com
 2022-01-21

Cover picture for the articleIn the CheckMate 649 trial, durable survival benefit was achieved with Nivolumab plus chemotherapy in patients with gastric or gastroesophageal junction cancer. In the CheckMate 649 trial (NCT02872116), durable survival benefit was achieved with Nivolumab (Opdivo) plus chemotherapy in patients with gastric or gastroesophageal junction (GEJ) cancer, data presented at the...

www.targetedonc.com

Comments / 0

Comments / 0